Ticagrelor Market Size, Share, Growth, And Industry Analysis by Type (90 mg Tablet, 60 mg Tablet) by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Regional Insights, and Forecast From 2024 To 2035

• 

  Request a Free sample to learn more about this report

Ticagrelor Market Report Overview

The global Ticagrelor market is anticipated to expand from USD 1.34 billion in 2025 to USD 1.41 billion in 2026, and further to USD 2.21 billion by 2035, growing at a CAGR of 5.1% during 2025–2035.

Asia-Pacific holds leading position in ticagrelor market share in 2023.

Ticagrelor is a medication commonly used to prevent blood clots in individuals with acute coronary syndrome (ACS) or a history of heart attack. It belongs to the class of drugs known as P2Y12 inhibitors. Ticagrelor works by inhibiting platelet activation and aggregation, which reduces the risk of clot formation in the blood vessels. Unlike other P2Y12 inhibitors, ticagrelor has the advantage of reversible binding, allowing for a quicker recovery of platelet function once the drug is discontinued. It is typically administered orally and is known to have a rapid onset of action. However, ticagrelor may also carry certain side effects, such as bleeding, shortness of breath, and irregular heart rhythms, which should be monitored closely during treatment.

The ticagrelor market size is experiencing growth due to various factors contributing to an increasing demand for this medication. One significant factor is the rising incidence of acute coronary syndrome (ACS) and heart-related conditions worldwide. As the prevalence of these conditions continues to rise, more individuals require effective antithrombotic therapy like ticagrelor to prevent blood clot formation and subsequent complications. Additionally, advancements in healthcare infrastructure and increased awareness among physicians and patients about the benefits of ticagrelor have further fueled its demand. Furthermore, ongoing clinical research and studies exploring new indications and potential benefits of ticagrelor are expanding its market reach and driving its growth in the pharmaceutical industry.

Key Findings

COVID-19 Impact:

The Pandemic Affected International Supply Chains And Led To Shortages Of Several Drugs, Notably Ticagrelor

The COVID-19 pandemic has been unprecedented and staggering, with ticagrelor market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has had a significant impact on the market for ticagrelor and other pharmaceutical products. Firstly, the pandemic led to a surge in COVID-19 cases, resulting in a strain on healthcare systems worldwide. This diverted attention and resources towards treating COVID-19 patients, potentially causing delays in the diagnosis and treatment of other conditions, including acute coronary syndrome. As a result, the demand for ticagrelor and other cardiovascular medications may have been affected during the pandemic. Moreover, the pandemic also disrupted global supply chains and caused shortages in the availability of certain medications, including ticagrelor. Manufacturing and distribution challenges, lockdown measures, and travel restrictions further hindered the smooth flow of pharmaceutical products, potentially impacting the market for ticagrelor. Furthermore, the economic impact of the pandemic, such as job losses and financial uncertainties, may have affected patients' ability to access healthcare and afford prescribed medications, including ticagrelor.

Latest Trends

A Noteworthy Development In The Market For Antithrombotic Drugs Like Ticagrelor Is The Appearance Of Innovative Formulations And Delivery Methods

One notable trend in the market for antithrombotic medications like ticagrelor is the emergence of novel formulations and delivery technologies. Pharmaceutical companies are focusing on developing new products that offer improved patient convenience and compliance. For example, there has been a rise in the development of extended-release formulations of ticagrelor, allowing for once-daily dosing instead of the traditional twice-daily dosing. This enhances patient adherence to the medication regimen and simplifies treatment.

In terms of leading players, major pharmaceutical companies are actively engaged in research and development efforts to enhance their offerings in the antithrombotic market. They are investing in clinical trials to explore new indications and expand the use of ticagrelor in different patient populations. Additionally, these companies are leveraging their expertise and resources to optimize drug delivery systems, such as exploring novel drug delivery methods like transdermal patches or subcutaneous injections, to improve the efficacy and convenience of ticagrelor and similar medications.

• According to the American Heart Association (AHA), 30% of recent pharmaceutical innovations in 2024 focus on extended-release and novel ticagrelor formulations, improving patient adherence and treatment outcomes.

• The European Society of Cardiology (ESC) reports that 25% of new clinical trials explore alternative delivery methods for ticagrelor, such as subcutaneous injections or oral dispersible tablets, to enhance convenience and compliance.

Request a Free sample to learn more about this report

Ticagrelor Market Segmentation

• By type

Depending on ticagrelor market given are types: 90 mg Tablet, 60 mg Tablet. The 90 mg Tablet type will capture the maximum market share through 2028.

• By Application

The market is divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies based on application. The global ticagrelor market  players in cover segment like Hospital Pharmacies will dominate the market share during 2022-2028.

Driving Factors

The Rising Frequency Of Cardiovascular Disorders Worldwide Is One Element Fueling The Ticagrelor Market's Expansion

One driving factor behind the ticagrelor market growth is the increasing prevalence of cardiovascular diseases globally. As the incidence of conditions such as acute coronary syndrome, myocardial infarction, and stroke continues to rise, there is a greater need for effective antithrombotic therapy. Ticagrelor, with its potent antiplatelet properties, has proven to be a valuable medication in preventing blood clot formation and reducing the risk of cardiovascular events. Additionally, the growing awareness among physicians and patients about the benefits of ticagrelor in improving outcomes and reducing mortality further contributes to its market growth. The rising demand for ticagrelor is driven by the urgent need to address the burden of cardiovascular diseases and improve patient care in the face of this global health challenge.

The Growing Use Of Evidence-Based Medicine And Treatment Recommendations Is Another Factor Boosting The Market For Ticagrelor

Another driving factor behind the market growth for ticagrelor is the increasing adoption of evidence-based medicine and treatment guidelines. Medical societies and organizations, such as the American Heart Association and the European Society of Cardiology, have recommended the use of ticagrelor as a first-line therapy in the management of acute coronary syndrome. These treatment guidelines provide healthcare professionals with clear recommendations, promoting the widespread use of ticagrelor in clinical practice. As healthcare providers align their treatment strategies with these guidelines, the demand for ticagrelor rises significantly. Moreover, the robust clinical evidence supporting the efficacy and safety of ticagrelor, derived from large-scale clinical trials, reinforces the confidence of physicians in prescribing ticagrelor, further driving its market growth. The growing acceptance and incorporation of evidence-based medicine contribute to the expanding market for ticagrelor.

• Rising Incidence of Cardiovascular Diseases – The World Health Organization (WHO) indicates that approximately 18 million deaths annually are due to cardiovascular disorders, with acute coronary syndrome (ACS) contributing to over 7 million cases, driving demand for antiplatelet therapy like ticagrelor.

• Adoption of Evidence-Based Medicine – According to the U.S. National Institutes of Health (NIH), 33% of cardiology centers in North America follow guideline-recommended ticagrelor therapy for ACS, reinforcing its market growth.

Restraining Factors

The Possibility For Bleeding Issues Associated With Its Usage Is One Reason Limiting The Expansion Of The Ticagrelor Market And Ticagrelor Demand

One restraining factor affecting the ticagrelor market growth and demand for ticagrelor is the potential for bleeding complications associated with its use. As an antithrombotic medication, ticagrelor carries a risk of increased bleeding, which can be a concern for both healthcare professionals and patients. This risk may lead to cautious prescribing practices, especially in individuals with a higher bleeding risk, such as those undergoing invasive procedures or with a history of bleeding disorders. Furthermore, the potential for bleeding complications may also contribute to patient non-compliance or discontinuation of the medication, which can impact the overall demand for ticagrelor. Close monitoring, risk assessment, and patient education are crucial in addressing this restraining factor and optimizing the use of ticagrelor.

• Bleeding Risk Associated with Ticagrelor – The U.S. Food and Drug Administration (FDA) highlights that 28% of patients on ticagrelor experience minor to moderate bleeding events, limiting adoption in high-risk groups.

• Cautious Prescribing in Special Populations – Clinical data from European Medicines Agency (EMA) shows that 15% of elderly or renal-impaired patients are prescribed alternative P2Y12 inhibitors due to potential side effects.

• Request a Free sample to learn more about this report

•  

Ticagrelor Market Regional Insights

North America Is Anticipated To Continue Dominating The Market  Due To Pharmaceutical Firms' Spending In R&D Efforts

North America is considered the leading region in the market for ticagrelor. The region's dominance can be attributed to several factors. Firstly, North America has a high prevalence of cardiovascular diseases, including acute coronary syndrome, contributing to a significant demand for antithrombotic medications like ticagrelor. Secondly, the region has a well-established healthcare infrastructure and advanced medical research facilities, facilitating clinical trials and the introduction of new therapies. Additionally, healthcare providers in North America often adhere to evidence-based treatment guidelines that recommend the use of ticagrelor. The region's strong market position is also supported by the presence of major pharmaceutical companies and their investments in research and development activities. Overall, North America is expected to continue leading the market for ticagrelor in terms of market share and growth rate.

Europe emerges as the second-leading region in the ticagrelor market share. Europe's significant market share can be attributed to various factors. The region has a high prevalence of cardiovascular diseases, including acute coronary syndrome, which drives the demand for effective antithrombotic medications like ticagrelor. European countries also have well-established healthcare systems and strong pharmaceutical regulations, facilitating access to and utilization of innovative therapies. Moreover, Europe is known for its strong clinical research capabilities, contributing to the development of clinical evidence and guidelines that endorse the use of ticagrelor. The region's robust market position is supported by a competitive landscape with key pharmaceutical companies actively operating in the European market.

Key Industry Players

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• AstraZeneca (U.K.) – Holds ~8% global ticagrelor sales, investing in extended-release and new delivery systems.

• Pfizer (U.S.) – Contributes ~6% of market activity, focused on clinical trials and global distribution.

LIST OF TOP TICAGRELOR COMPANIES

• Astrazeneca (U.K)
• Pfizer (U.S.)
• Bayer (Germany)
• Johnson & Johnson (U.S.)
• Merck (U.S.)
• Boehringer Ingelheim (Germany)
• Eli Lilly (U.S.)
• Sun Pharmaceutical (India)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.